AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 525649: N,N-Dimethyl-N'-propyl-benzamidine

Chemical compound data from PubChem database. IUPAC Name: N,N-dimethyl-N'-propylbenzenecarboximidamide. Molecular Formula: C12H18N2. Molecular Weight: 190.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
DEV DQS Normal weight, overweight, and obesity among adults aged 20 and over, by selected characteristics: United States

Data on overweight and obesity among adults aged 20 and over in the United States, by selected characteristics, including sex, age, race, Hispanic origin, and poverty level. Data are from Health, United States. SOURCE: National Center for Health Statistics, National Health and Nutrition Examination Survey.
Search, visualize, and download these and other estimates from over 120 health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.
2010 State Profile — Georgia

This state profile includes data from facilities in Georgia that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in Georgia. In Georgia, 243 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 18,928 clients in substance abuse treatment on March 31, 2010. The survey response rate in Georgia was 88.1%.
Family Search and Engagement (FSE) Program Manual

This PII grantee program manual provides detailed information about the implementation process of the Washoe County Department of Social Services (WCDSS) Family Search and Engagement (FSE) program. The purpose of the manual is to assist others in the field in replicating or adapting FSE for their local use. Readers will find background information, lessons learned, and other practical information based on the experience of the WCDSS team. The manual can be especially helpful if you are considering implementation of the intervention, interested in addressing the needs of similar target populations, or interested in lessons learned from real-world implementation experiences. Together, the PII program manuals help to build a base of replicable interventions that can serve the complex needs of diverse communities of children and families.

Metadata-only record linking to the original dataset. Open original dataset below.
PLACES: Census Tract Data (GIS Friendly Format), 2023 release

This dataset contains model-based census tract level estimates in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2021 or 2020 data, Census Bureau 2010 population estimates, and American Community Survey (ACS) 2015–2019 estimates. The 2023 release uses 2021 BRFSS data for 29 measures and 2020 BRFSS data for 7 measures (all teeth lost, dental visits, mammograms, cervical cancer screening, colorectal cancer screening, core preventive services among older adults, and sleeping less than 7 hours) that the survey collects data on every other year. These data can be joined with the census tract 2015 boundary file in a GIS system to produce maps for 36 measures at the census tract level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software.
https://cdcarcgis.maps.arcgis.com/home/item.html?id=2c3deb0c05a748b391ea8c9cf9903588
Special Vaccine Locations

List of sites that guarantee specific, non-flu vaccines will be in-stock and available for the time period indicated in each record. For flu shot locations, go to https://data.cityofchicago.org/Health-Human-Services/Flu-Shot-Locations-2014-Present/w3hg-pyhz.

Note for using this dataset that it is always recommended that individuals contact their healthcare provider or closest pharmacy to check on vaccine availability prior to walking in for vaccination. Each vaccine has a filtered view showing only records from that vaccine and blank filter conditions that can be used to filter further by time. These filtered views can be used for almost all purposes as if they were datasets, although any additional criteria added by a user would need to be saved to a new filtered view in order to use it in this manner. This dataset approximately follows https://github.com/codeforamerica/flu-shot-spec/blob/master/data-format.csv and is designed for use by https://github.com/tkompare.

For more information about CDPH Vaccines/Shots/Immunizations, go to https://www.chicago.gov/city/en/depts/cdph/provdrs/health_protection_and_response/svcs/immunization1.html.
Compound 526664: Methyl 3,6,7-tris(acetyloxy)cholan-24-oate

Chemical compound data from PubChem database. IUPAC Name: methyl 4-(3,6,7-triacetyloxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate. Molecular Formula: C31H48O8. Molecular Weight: 548.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Medicare Post-Acute Care Utilization - Skilled Nursing Facility by Geography, Provider and Service

The Medicare Post-Acute Care (PAC) Utilization - Skilled Nursing Facility (SNF) by Geography, Provider and Service supplemental dataset provides detailed information on payments and utilization for SNFs. For Fiscal Years (FY)s 2014–2019, data is organized by provider and Resource Utilization Group (RUG) type. Starting in FY 2020, following the shift to the Patient-Driven Payment Model (PDPM), the dataset no longer includes RUG-level data. Instead, it features therapy minutes by discipline, stays by clinical category, and the percentage of stays involving depression or swallowing disorders.
Quality Assurance Reporting Requirements (QARR) Health Disparities 2023

This dataset includes Medicaid Managed Care, Commercial HMO, and Commercial PPO performance data from the Quality Assurance Reporting Requirements (QARR) by member demographic characteristics. QARR is largely based on measures of quality developed and published by the National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS®). Plans are required to submit quality performance data each year. Demographic information analyzed in this report includes members’ sex, age, race/ethnicity, Medicaid aid category, cash assistance status, behavioral health conditions including serious mental illness (SMI) and substance use disorder (SUD), payer status, and region of residence. Measuring the quality of care, and the ability to measure disparities in care is an important first step to a better understanding of the underlying factors that drive differences in care among certain populations within Medicaid Managed Care, Commercial HMO, and Commercial PPO.

The data is published annually for the Medicaid Managed Care Reports for Quality Performance: Health Care Disparities in New York State http://www.health.ny.gov/health_care/managed_care/reports/
Mutation analysis of the CHK2 gene in breast carcinoma and other cancers

Background
          Mutations in the CHK2 gene at chromosome 22q12.1 have been reported in families with Li-Fraumeni syndrome. Chk2 is an effector kinase that is activated in response to DNA damage and is involved in cell-cycle pathways and p53 pathways.
        
        
          Methods
          We screened 139 breast tumors for loss of heterozygosity at chromosome 22q, using seven microsatellite markers, and screened 119 breast tumors with single-strand conformation polymorphism and DNA sequencing for mutations in the CHK2 gene.
        
        
          Results
          Seventy-four of 139 sporadic breast tumors (53%) show loss of heterozygosity with at least one marker. These samples and 45 tumors from individuals carrying the BRCA2 999del5 mutation were screened for mutations in the CHK2 gene. In addition to putative polymorphic regions in short mononucleotide repeats in a non-coding exon and intron 2, a germ line variant (T59K) in the first coding exon was detected. On screening 1172 cancer patients for the T59K sequence variant, it was detected in a total of four breast-cancer patients, two colon-cancer patients, one stomach-cancer patient and one ovary-cancer patient, but not in 452 healthy individuals. A tumor-specific 5' splice site mutation at site +3 in intron 8 (TTgt [a → c]atg) was also detected.
        
        
          Conclusion
          We conclude that somatic CHK2 mutations are rare in breast cancer, but our results suggest a tumor suppressor function for CHK2 in a small proportion of breast tumors. Furthermore, our results suggest that the T59K CHK2 sequence variant is a low-penetrance allele with respect to tumor growth.
Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health

This study will examine the associations between motivations for misuse of prescription medications and sociodemographic factors, SUD, MDE, mental illness, and suicidal ideation.Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health(link is external)
Foster Care: A Path to Reunification – Part 2

This Child Welfare Information Gateway Podcast is available on Apple Podcasts
  
  

, GooglePlay
  
  

, Spotify
  
  

, Stitcher
  
  

, SoundCloud
  
  

, and the Child Welfare Information Gateway
  
  

 website. Subscribe to receive new episodes as they are released.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E400250-T1: [Translated] SOLID PHASE AGENT FOR VASCULAR OCCLUSION WITH IMMOBILIZED THROMBOCYTE BINDING SUBSTANCE

The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent, causing vessel occlusion.
Program Instruction (PI-15-03)

This Program Instruction (PI) provides instruction to States on the June 30, 2015, submission of: (1) the first Annual Progress and Services Report (APSR) to the 2015-2019 Child and Family Services Plan (CFSP) for the Stephanie Tubbs Jones Child Welfare Services (CWS), the Promoting Safe and Stable Families (PSSF) and Monthly Caseworker Visit Grant programs; and the Chafee Foster Care Independence Program (CFCIP) and the Education and Training Vouchers (ETV) Program; (2) the Child Abuse Prevention and Treatment Act (CAPTA) State Plan update; and (3) the CFS-101, Part I, Annual Budget Request, Part II, Annual Summary of Child and Family Services, and Part III, Annual Expenditure Report- Title IV-B, subparts 1 and 2, CFCIP, and ETV.

PI-15-03 (PDF)

Fiscal Year 2015 Allotment Title IV-B Subpart 1 Stephanie Tubbs Jones Child Welfare Services
Fiscal Year 2015 Allotment Title IV-B Subpart 2 Promoting Safe and Stable Families
Fiscal Year 2015 Allotment for Title IV-B, Subpart 2 Monthly Caseworker Visit Funds
Fiscal Year 2015 Allotment for CAPTA
Fiscal Year 2015 Allotment for Chafee Foster Care Independence Program
Fiscal Year 2015 Allotment for Education and Training Vouchers

CFS-101 Part I:  Annual Budget Request for Title IV-B, subparts 1 and 2, CAPTA, Chafee Foster Care Independence (CFCIP) and Education and Training Voucher (ETV) Program Instructions
CFS-101 Part I:  Annual Budget Request for Title IV-B, subparts 1 and 2, CAPTA, Chafee Foster Care Independence (CFCIP) and Education and Training Voucher (ETV) Program Form (Excel (XLSX) - 15 KB)
CFS-101, Part II:  Annual Summary of Child and Family Services Instructions
CFS-101, Part II:  Annual Summary of Child and Family Services Form (Excel (XLSX) - 15 KB)
CFS-101, Part III:  Annual Expenditures for Title IV-B, subparts 1 and 2, CAPTA, Chafee Foster Care Independence (CFCIP) and Education and Training Voucher (ETV) Instructions
CFS-101, Part III:  Annual Expenditures for Title IV-B, subparts 1 and 2, CAPTA, Chafee Foster Care Independence (CFCIP) and Education and Training Voucher (ETV) Form (Excel (XLSX) - 14 KB)

CB Regional Program Managers

NCANDS State Contact List

Annual Reporting of Education and Training Vouchers Awarded (Word (DOCX) - 17 KB)

Metadata-only record linking to the original dataset. Open original dataset below.
Youth Information Form: Data from Runaway and Homeless Youth Programs, 1987-1990

These data were gathered from federally funded runaway and homeless youth shelters during 1988-1989.  Data were collected on approximately 87,000 youth who received services from runaway and homeless youth programs. The following types of information are included in the data set:  demographic characteristics, youth and family presenting problems at intake (including history of abuse and neglect), and services provided by the shelter.

Investigators: Office of Human Development Services/ACYF
Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progression

We examined the stage specificity and heterogeneity of 18p11 alterations in a series of tumors representing 96 microdissected samples. Significant loss of heterozygosity (LOH) (63%) was found, with 56% occurring early in ductal carcinoma in situ. Although most cases indicated LOH was clonally inherited, heterogeneity for 18p LOH occurred in 27% of tumors. When compared with other LOH data, 18p LOH was found in conjunction with allelic deletion on 3p, 9p, 17p and 17q, while 13q, 16q, and 11p were less frequently associated. These analyses suggest chromosome 18p11 alteration is a common and early event in breast disease.
COVID-19 Vaccination Locations - Historical

NOTE: This dataset has been retired and marked as historical-only.

Select locations offering COVID-19 vaccination in Chicago. This is not an exhaustive list of all providers currently offering COVID-19 vaccine. Many providers are not listed on the map because they will start by providing vaccine to their current patients before expanding to others. Your first contact should be your health care provider, including your primary care provider, health clinic, or hospital where you have gotten medical care in the past. Check your provider’s website, electronic application (e.g., MyChart), or office recorded message for details on vaccine availability. Providers are also reaching out directly to schedule appointments with their existing patients, prioritizing those who are older with more underlying conditions. Check the details associated with each provider prior to calling or showing up at the office or pharmacy.

There is a phased roll-out of the COVID-19 vaccine in Chicago with a very limited supply, so certain groups are prioritized. Currently, vaccination is available by appointment only for eligible individuals. The vaccine will be offered at no cost to all Chicagoans who want it, but patience is needed while vaccine quantities increase. Learn more about Chicago's vaccination phases and who is currently eligible here: https://www.chicago.gov/city/en/sites/covid19-vaccine/home/vaccine-distribution-phases.html 

For a map of these locations, see https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccination-Locations-Map/4shi-izjg

The City of Chicago does not endorse any of the listed organizations. This list is provided only as a convenience. See the full disclaimer: https://www.chicago.gov/content/dam/city/sites/covid-19-vaccine/Documents/Disclaimer.pdf

For more information on COVID-19 vaccine, see https://www.chicago.gov/city/en/sites/covid19-vaccine/home.html. 

To get the latest updates on Chicago's vaccination plan and be notified when different groups are eligible to receive COVID-19 vaccine, sign up for Chi COVID Coach: https://covidcoach.chicago.gov/

For all datasets related to COVID-19, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=covid-19.
Compound 529481: 3-Methyl-2,4-nonanedione

Chemical compound data from PubChem database. IUPAC Name: 3-methylnonane-2,4-dione. Molecular Formula: C10H18O2. Molecular Weight: 170.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2020-2021 Nationwide Blood Donor Seroprevalence Survey Infection-Induced Seroprevalence Estimates

CDC is collaborating with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), Vitalant Research Institute (VRI), Westat Inc., and numerous blood collection organizations across the United States to conduct a nationwide COVID-19 seroprevalence survey of blood donors. This is the largest nationwide COVID-19 seroprevalence survey to date. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Infection-induced seroprevalence estimates the proportion of the population with evidence of previous SARS-CoV-2 infection and refers to the prevalence of the population with both anti-S and anti-N antibodies.

This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence

Additional information is available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/blood-bank-serosurvey.html
Search for intracranial aneurysm susceptibility gene(s) using Finnish families

Background
          Cerebrovascular disease is the third leading cause of death in the United States, and about one-fourth of cerebrovascular deaths are attributed to ruptured intracranial aneurysms (IA). Epidemiological evidence suggests that IAs cluster in families, and are therefore probably genetic. Identification of individuals at risk for developing IAs by genetic tests will allow concentration of diagnostic imaging on high-risk individuals. We used model-free linkage analysis based on allele sharing with a two-stage design for a genome-wide scan to identify chromosomal regions that may harbor IA loci.
        
        
          Methods
          We previously estimated sibling relative risk in the Finnish population at between 9 and 16, and proceeded with a genome-wide scan for loci predisposing to IA. In 85 Finnish families with two or more affected members, 48 affected sibling pairs (ASPs) were available for our genetic study. Power calculations indicated that 48 ASPs were adequate to identify chromosomal regions likely to harbor predisposing genes and that a liberal stage I lod score threshold of 0.8 provided a reasonable balance between detection of false positive regions and failure to detect real loci with moderate effect.
        
        
          Results
          Seven chromosomal regions exceeded the stage I lod score threshold of 0.8 and five exceeded 1.0. The most significant region, on chromosome 19q, had a maximum multipoint lod score (MLS) of 2.6.
        
        
          Conclusions
          Our study provides evidence for the locations of genes predisposing to IA. Further studies are necessary to elucidate the genes and their role in the pathophysiology of IA, and to design genetic tests.
Patent AT-E401300-T1: [Translated] METHOD FOR PRODUCING VALSARTAN AND PRECURSOR THEREOF

This invention relates to a process for preparing intermediates useful in preparing Valsartan and to a process for preparing the latter, together with synthesis intermediates of formula (IV), (V) and (VI), useful for manufacturing a medicament for the treatment of arterial hypertension or heart failure. The process for preparing Valsartan permits it to be prepared on an industrial scale with high yields and without racemisation problems, in addition to using simple and available starting products. The invention also provides a process for preparing the intermediate of formula (VI), from an intermediate of formula (V) that does not require protection of the carboxylic acid prior to N-acylation.
Compound 525045: N-(3,4-dichlorophenyl)pentanamide

Chemical compound data from PubChem database. IUPAC Name: N-(3,4-dichlorophenyl)pentanamide. Molecular Formula: C11H13Cl2NO. Molecular Weight: 246.13. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525503: 6-Methyl-4,5-dithia-1-heptene

Chemical compound data from PubChem database. IUPAC Name: 2-(prop-2-enyldisulfanyl)propane. Molecular Formula: C6H12S2. Molecular Weight: 148.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528065: tert-Butyl(dimethyl)silyl 2-([tert-butyl(dimethyl)silyl]amino)-3-([tert-butyl(dimethyl)silyl]oxy)propanoate

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2-[[tert-butyl(dimethyl)silyl]amino]-3-[tert-butyl(dimethyl)silyl]oxypropanoate. Molecular Formula: C21H49NO3Si3. Molecular Weight: 447.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Address-Based Sampling Research Report

If the Substance Abuse and Mental Health Services Administration (SAMHSA) is to move NSDUH to a hybrid ABS/field-enumerated frame, several questions will need to be answered, procedures will need to be developed and tested, and costs and benefits will need to be weighed. This report outlines what is known to date, how it may be applied to NSDUH, and what additional considerations need to be addressed.
Ibrutinib

Imbruvica (ibrutinib) is an oral prescription medication that acts as a kinase inhibitor to help treat certain blood cancers. Available as tablets (140mg, 230mg, 420mg, 560mg), capsules (70mg, 140mg), and suspension (70mg/mL), it's manufactured by Pharmacyclics LLC. This information was generated using AI and is provided for informational and research purposes only.
2022 Uniform Reporting System (URS) Table For Federated States of Micronesia

This is the 2022 Uniform Reporting System (URS) Output Tables for Federated States of Micronesia. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence-based practices, and utilization measures providing an overview of state mental health delivery systems.